Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Marshalls warns of soft activity levels in key markets

(Sharecast News) - Landscaping products manufacturer Marshalls warned on Friday that activity levels in its key markets had softened from the end of May and said it did not see "any immediate catalyst" for improvement for the remainder of 2025. Interim revenues came to £319.0m, up 4% year-on-year, with volume growth being "partially offset" by weaker pricing and product mix.

Landscaping products revenue contracted by 1% year-on-year to £135.0m, a "significant improvement" on the 11% year-on-year reduction reported in H224, underpinned by improved engagement with key customers leading to volume gains and regaining of market share.

However, Marshalls cautioned that landscaping end markets "remain challenging", with structural overcapacity in the UK supply chain continuing to exert downward pressure on prices.

Marshalls said profitability "fell short" of original expectations and now, assuming that headwinds continue with no increase in market activity levels, these same headwinds were expected to result in continued pressure on profitability in H2.

Elsewhere, building products revenue was up 5% at £86.0m, and roofing products revenue was 11% higher at £98.0m.

"Being mindful of continuing uncertainty in the macroeconomic environment, the board currently sees no improvement in market activity levels through the remainder of 2025. Accordingly, its FY expectations for the group have reduced and it now expects adjusted profit before tax to be in the range of £42.0m and £46.0m in 2025," said Marshalls.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.